Annexa 4 trial6/14/2023 ![]() Thrombotic events (11%) and death rates (12%) were consistent with previous ANNEXA-4 trial results and with the high background thrombotic risk of the enrolled patient population. ![]() ![]() In addition, 83% of these patients achieved excellent or good haemostasis (stoppage of bleeding) over a 12-hour period following treatment with AndexXa. Interim data from 228 patients (of which 132 were adjudicated for efficacy) showed that AndexXa rapidly and significantly reversed anti-Factor Xa activity (the anticoagulant mechanism of these drugs) when administered as a bolus, and sustained this reversal when followed by a 120-minute infusion. ![]()
0 Comments
Leave a Reply. |